Joshua Rosenberg, MD, leads a discussion around the REVISIT trial, which was a phase 3, randomized, multinational, open-label study that evaluated the efficacy and safety of aztreonam-avibactam compared to meropenem in hospitalized adults with serious Gram-negative bacterial infections, specifically complicated intra-abdominal infections (cIAI) and hospital-acquired/ventilator-associated pneumonia (HAP/VAP).
